

Georg A Bjarnason

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/910943/publications.pdf>

Version: 2024-02-01

253
papers

16,266
citations

18436

62
h-index

16605

123
g-index

256
all docs

256
docs citations

256
times ranked

16276
citing authors

#	ARTICLE	IF	CITATIONS
1	Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3584-3590.	0.8	2,020
2	Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis. <i>Cancer Cell</i> , 2009, 15, 232-239.	7.7	1,624
3	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1814-1823.	13.9	1,004
4	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. <i>Lancet Oncology</i> , The, 2013, 14, 141-148.	5.1	808
5	Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. <i>Lancet Oncology</i> , The, 2009, 10, 757-763.	5.1	571
6	Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2014, 66, 704-710.	0.9	382
7	Circadian Expression of Clock Genes in Human Oral Mucosa and Skin. <i>American Journal of Pathology</i> , 2001, 158, 1793-1801.	1.9	337
8	Randomized Phase III Trial of Teme sirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 760-767.	0.8	331
9	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. <i>Lancet Oncology</i> , The, 2015, 16, 293-300.	5.1	299
10	Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 286-296.	5.1	239
11	Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. <i>European Urology</i> , 2014, 65, 577-584.	0.9	207
12	Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 3562-3569.	0.8	200
13	Circadian Rhythm in Rest and Activity: A Biological Correlate of Quality of Life and a Predictor of Survival in Patients with Metastatic Colorectal Cancer. <i>Cancer Research</i> , 2009, 69, 4700-4707.	0.4	195
14	Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. <i>Cancer</i> , 2013, 119, 2999-3006.	2.0	189
15	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3655-3663.	0.8	174
16	miRNA Profiling for Clear Cell Renal Cell Carcinoma: Biomarker Discovery and Identification of Potential Controls and Consequences of miRNA Dysregulation. <i>Journal of Urology</i> , 2011, 186, 1077-1083.	0.2	172
17	Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 12-19.	2.9	157
18	Circadian Variation in the Expression of Cell-Cycle Proteins in Human Oral Epithelium. <i>American Journal of Pathology</i> , 1999, 154, 613-622.	1.9	152

#	ARTICLE	IF	CITATIONS
19	miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. <i>British Journal of Cancer</i> , 2011, 105, 1741-1749.	2.9	152
20	miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. <i>Carcinogenesis</i> , 2013, 34, 2231-2239.	1.3	146
21	A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. <i>Lancet</i> , The, 2021, 397, 695-703.	6.3	146
22	Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-“Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1029-1039.	0.8	145
23	Lactate Dehydrogenase A is a potential prognostic marker in clear cell renal cell carcinoma. <i>Molecular Cancer</i> , 2014, 13, 101.	7.9	141
24	Chronotherapy and the molecular clock: Clinical implications in oncology. <i>Advanced Drug Delivery Reviews</i> , 2010, 62, 979-1001.	6.6	139
25	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. <i>European Urology</i> , 2016, 70, 358-364.	0.9	133
26	Sunitinib in metastatic renal cell carcinoma patients with brain metastases. <i>Cancer</i> , 2011, 117, 501-509.	2.0	126
27	Dynamic Microbubble Contrast-enhanced US to Measure Tumor Response to Targeted Therapy: A Proposed Clinical Protocol with Results from Renal Cell Carcinoma Patients Receiving Antiangiogenic Therapy. <i>Radiology</i> , 2011, 260, 581-590.	3.6	125
28	Spine stereotactic body radiotherapy for renal cell cancer spinal metastases: analysis of outcomes and risk of vertebral compression fracture. <i>Journal of Neurosurgery: Spine</i> , 2014, 21, 711-718.	0.9	125
29	Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. <i>Annals of Oncology</i> , 2012, 23, 1549-1555.	0.6	121
30	Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. <i>Annals of Oncology</i> , 2014, 25, 149-154.	0.6	121
31	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. <i>Lancet Oncology</i> , The, 2012, 13, 927-935.	5.1	112
32	Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 3671-3677.	0.8	112
33	Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. <i>Annals of Oncology</i> , 2012, 23, 3110-3116.	0.6	108
34	Scoring oral mucositis. <i>Oral Oncology</i> , 1998, 34, 63-71.	0.8	107
35	Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. <i>Canadian Urological Association Journal</i> , 2012, 1, S41-54.	0.3	107
36	The Clinical Utility of miR-21 as a Diagnostic and Prognostic Marker for Renal Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2012, 14, 385-392.	1.2	106

#	ARTICLE	IF	CITATIONS
37	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. <i>JAMA Network Open</i> , 2021, 4, e2021869.	2.8	104
38	Prediction of overall survival through circadian restâ€¢activity monitoring during chemotherapy for metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2012, 131, 2684-2692.	2.3	102
39	Circadian cancer therapy.. <i>Journal of Clinical Oncology</i> , 1993, 11, 1403-1417.	0.8	101
40	Comparison of Toxicity Associated With Early Morning Versus Late Afternoon Radiotherapy in Patients With Head-and-Neck Cancer: A Prospective Randomized Trial of the National Cancer Institute of Canada Clinical Trials Group (HN3). <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 166-172.	0.4	90
41	Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. <i>British Journal of Cancer</i> , 2015, 113, 1571-1580.	2.9	88
42	Validation of Patient's Self-Reported Social Functioning As an Independent Prognostic Factor for Survival in Metastatic Colorectal Cancer Patients: Results of an International Study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 2020-2026.	0.8	87
43	Quantitative proteomic analysis reveals potential diagnostic markers and pathways involved in pathogenesis of renal cell carcinoma. <i>Oncotarget</i> , 2014, 5, 506-518.	0.8	87
44	Circadian variation of cell proliferation and cell cycle protein expression in man: Clinical implications. , 2000, 4, 193-206.		87
45	An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. <i>European Journal of Cancer</i> , 2012, 48, 324-332.	1.3	84
46	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1020-1028.	0.8	83
47	Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 6023-6031.	3.2	81
48	The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. <i>Supportive Care in Cancer</i> , 2016, 24, 1097-1105.	1.0	81
49	Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e79-e85.	0.9	78
50	Rhythms in Human Gastrointestinal Mucosa and Skin. <i>Chronobiology International</i> , 2002, 19, 129-140.	0.9	75
51	CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib. <i>Cancer Imaging</i> , 2017, 17, 4.	1.2	75
52	Toward Biological Subtyping of Papillary Renal Cell Carcinoma With Clinical Implications Through Histologic, Immunohistochemical, and Molecular Analysis. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1618-1629.	2.1	75
53	Progressionâ€¢free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. <i>Cancer</i> , 2011, 117, 2637-2642.	2.0	74
54	Sunitinib in Metastatic Renal Cell Carcinoma: Recommendations for Management of Noncardiovascular Toxicities. <i>Oncologist</i> , 2011, 16, 543-553.	1.9	74

#	ARTICLE	IF	CITATIONS
55	Quantitative Proteomic Analysis in Metastatic Renal Cell Carcinoma Reveals a Unique Set of Proteins with Potential Prognostic Significance. <i>Molecular and Cellular Proteomics</i> , 2013, 12, 132-144.	2.5	73
56	miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma. <i>Molecular Therapy</i> , 2015, 23, 1748-1758.	3.7	73
57	Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 480-487.	0.8	72
58	Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101.. <i>Journal of Clinical Oncology</i> , 2011, 29, 4003-4003.	0.8	72
59	Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. <i>British Journal of Cancer</i> , 2014, 110, 648-655.	2.9	71
60	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. <i>European Urology</i> , 2014, 65, 1086-1092.	0.9	71
61	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. <i>European Urology</i> , 2019, 76, 861-867.	0.9	71
62	Dynamic contrast enhanced ultrasound for therapy monitoring. <i>European Journal of Radiology</i> , 2015, 84, 1650-1657.	1.2	65
63	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology</i> , 2017, 71, 204-209.	0.9	65
64	Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study. <i>European Urology</i> , 2021, 80, 693-700.	0.9	65
65	Are medical oncologists biased in their treatment of the large woman with breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2001, 66, 123-133.	1.1	64
66	First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. <i>British Journal of Cancer</i> , 2014, 110, 1917-1922.	2.9	64
67	Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 513-522.	1.9	64
68	From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. <i>Molecular Cancer</i> , 2009, 8, 20.	7.9	61
69	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Journal of Cancer</i> , 2016, 65, 102-108.	1.3	60
70	Low-dose Ultraviolet B Rays Alter the mRNA Expression of the Circadian Clock Genes in Cultured Human Keratinocytes. <i>Journal of Investigative Dermatology</i> , 2002, 119, 1220-1223.	0.3	58
71	Exploring the role of miRNAs in renal cell carcinoma progression and metastasis through bioinformatic and experimental analyses. <i>Tumor Biology</i> , 2012, 33, 131-140.	0.8	56
72	miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 136-144.	1.2	55

#	ARTICLE	IF	CITATIONS
73	Subjective sleep and overall survival in chemotherapy-naïve patients with metastatic colorectal cancer. <i>Sleep Medicine</i> , 2015, 16, 391-398.	0.8	55
74	Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. <i>Annals of Oncology</i> , 2011, 22, 145-148.	0.6	52
75	Galectin-1 has potential prognostic significance and is implicated in clear cell renal cell carcinoma progression through the HIF/mTOR signaling axis. <i>British Journal of Cancer</i> , 2014, 110, 1250-1259.	2.9	52
76	First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2018, 74, 309-321.	0.9	51
77	Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. <i>Science Translational Medicine</i> , 2015, 7, 282ra50.	5.8	48
78	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. <i>Targeted Oncology</i> , 2013, 8, 203-209.	1.7	47
79	Circadian rest-activity rhythm as an objective biomarker of patient-reported outcomes in patients with advanced cancer. <i>Cancer Medicine</i> , 2018, 7, 4396-4405.	1.3	45
80	Circadian Disruption, Fatigue, and Anorexia Clustering in Advanced Cancer Patients: Implications for Innovative Therapeutic Approaches. <i>Integrative Cancer Therapies</i> , 2009, 8, 361-370.	0.8	44
81	Using the Delphi Technique to Improve Clinical Outcomes Through the Development of Quality Indicators in Renal Cell Carcinoma. <i>Journal of Oncology Practice</i> , 2013, 9, e262-e267.	2.5	43
82	Does the Time of Radiotherapy Affect Treatment Outcomes? A Review of the Literature. <i>Clinical Oncology</i> , 2017, 29, 231-238.	0.6	42
83	Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. <i>European Urology</i> , 2015, 68, 506-515.	0.9	41
84	Irinotecan-associated pulmonary toxicity. <i>Anti-Cancer Drugs</i> , 2000, 11, 709-713.	0.7	40
85	Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. <i>Cancer</i> , 2013, 119, 2564-2573.	2.0	40
86	Symptoms associated with circadian rest-activity rhythm disruption in 237 patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1-1.	0.8	40
87	A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2007, 60, 135-141.	1.1	37
88	Prediction of Survival by Neutropenia According To Delivery Schedule of Oxaliplatin+5-Fluorouracil+Leucovorin for Metastatic Colorectal Cancer in a Randomized International Trial (EORTC 05963). <i>Chronobiology International</i> , 2011, 28, 586-600.	0.9	37
89	Characterizing the outcomes of metastatic papillary renal cell carcinoma. <i>Cancer Medicine</i> , 2017, 6, 902-909.	1.3	37
90	Phase II Study of Troxacitabine (BCH-4556) in Patients With Advanced and/or Metastatic Renal Cell Carcinoma: A Trial of the National Cancer Institute of Canada-Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 1524-1529.	0.8	36

#	ARTICLE	IF	CITATIONS
91	Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 33, 221-228.	1.1	35
92	Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 171-178.	0.8	35
93	Improved Flow Measurement Using Microbubble Contrast Agents and Disruption-Replenishment: Clinical Application to Tumour Monitoring. <i>Ultrasound in Medicine and Biology</i> , 2011, 37, 1210-1221.	0.7	33
94	First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. <i>Canadian Urological Association Journal</i> , 2017, 11, 112.	0.3	32
95	Diurnal protein expression in blood revealed by high throughput mass spectrometry proteomics and implications for translational medicine and body time of day. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2007, 293, R1430-R1437.	0.9	31
96	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2019, 2, 643-648.	2.6	31
97	Canadian guideline on genetic screening for hereditary renal cell cancers. <i>Canadian Urological Association Journal</i> , 2013, 7, 319.	0.3	30
98	Relationship between subjective and actigraphy-measured sleep in 237 patients with metastatic colorectal cancer. <i>Quality of Life Research</i> , 2017, 26, 2783-2791.	1.5	29
99	Effects of circadian rhythms and treatment times on the response of radiotherapy for painful bone metastases. <i>Annals of Palliative Medicine</i> , 2017, 6, 14-25.	0.5	29
100	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>European Urology Oncology</i> , 2020, 3, 530-539.	2.6	29
101	The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib. <i>European Radiology</i> , 2018, 28, 2281-2290.	2.3	28
102	Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 4027-4027.	0.8	28
103	Hypertension Management in Patients with Renal Cell Cancer Treated with Anti-Angiogenic Agents. <i>Current Oncology</i> , 2012, 19, 202-208.	0.9	27
104	Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 354-358.	0.9	26
105	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 102-111.	2.6	26
106	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, e127-e131.	0.9	25
107	The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. <i>European Journal of Cancer</i> , 2019, 108, 69-77.	1.3	25
108	Local control and patterns of failure for “Radioresistant” spinal metastases following stereotactic body radiotherapy compared to a “Radiosensitive” reference. <i>Journal of Neuro-Oncology</i> , 2021, 152, 173-182.	1.4	24

#	ARTICLE	IF	CITATIONS
109	Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2008, 26, 5114-5114.	0.8	24
110	Sunitinib in patients with or without prior nephrectomy (Nx) in an expanded access trial of metastatic renal cell carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2008, 26, 5124-5124.	0.8	24
111	Real-World Outcomes of Nivolumab and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Current Oncology</i> , 2019, 26, 175-179.	0.9	23
112	Morbidity and Mortality of Radical Nephrectomy for Patients With Disseminated Cancer: An Analysis of the National Surgical Quality Improvement Program Database. <i>Urology</i> , 2016, 95, 95-102.	0.5	22
113	Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. <i>Cancer Medicine</i> , 2021, 10, 1212-1221.	1.3	22
114	Could time of whole brain radiotherapy delivery impact overall survival in patients with multiple brain metastases?. <i>Annals of Palliative Medicine</i> , 2016, 5, 267-279.	0.5	20
115	Platelet to white blood cell ratio predicts 30-day postoperative infectious complications in patients undergoing radical nephrectomy for renal malignancy. <i>Canadian Urological Association Journal</i> , 2017, 11, E414-20.	0.3	20
116	Outpatient 5-Fluorouracil, Folinic Acid and Cisplatin in Patients with Advanced Esophageal Carcinoma. <i>Acta Oncologica</i> , 1999, 38, 255-259.	0.8	19
117	Management of Kidney Cancer: Canadian Kidney Cancer Forum Consensus Update 2011. <i>Canadian Urological Association Journal</i> , 2012, 6, 16-22.	0.3	19
118	Sunitinib in metastatic renal cell carcinoma (mRCC) patients (pts) with brain metastases (mets): data from an expanded access trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 5094-5094.	0.8	19
119	Quantifying Vascular Heterogeneity Using Microbubble Disruption-Replenishment Kinetics in Patients With Renal Cell Cancer. <i>Investigative Radiology</i> , 2014, 49, 116-123.	3.5	18
120	Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. <i>Canadian Urological Association Journal</i> , 2015, 9, 164.	0.3	18
121	The emerging roles of stereotactic ablative radiotherapy for metastatic renal cell carcinoma. <i>Current Opinion in Supportive and Palliative Care</i> , 2014, 8, 258-264.	0.5	17
122	Use of Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Economic Impact in a Canadian Real-Life Setting. <i>Current Oncology</i> , 2018, 25, 576-584.	0.9	16
123	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. <i>Canadian Urological Association Journal</i> , 2018, 12, 173-80.	0.3	16
124	Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma. <i>Current Oncology</i> , 2011, 18 Suppl 2, S11-9.	0.9	16
125	Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4594-TPS4594.	0.8	15
126	Cytoreductive nephrectomy in metastatic papillary renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 581-581.	0.8	15

#	ARTICLE	IF	CITATIONS
127	S100A11 is a potential prognostic marker for clear cell renal cell carcinoma. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 63-71.	1.7	14
128	A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers. <i>Targeted Oncology</i> , 2017, 12, 655-661.	1.7	14
129	A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 387-387.	0.8	14
130	Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. <i>European Journal of Cancer</i> , 2022, 171, 124-132.	1.3	14
131	Impact of Acquisition Method and Region of Interest Placement on Inter-observer Agreement and Measurement of Tumor Response to Targeted Therapy Using Dynamic Contrast-Enhanced Ultrasound. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 763-768.	0.7	13
132	Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). <i>Kidney Cancer</i> , 2017, 1, 41-47.	0.2	13
133	Determining Generalizability of the Canadian Kidney Cancer information system (CKCis) to the Entire Canadian Kidney Cancer Population. <i>Canadian Urological Association Journal</i> , 2020, 14, E499-E506.	0.3	13
134	Microbubble ultrasound (DCE-US) compared to DCE-MRI and DCE-CT for the assessment of vascular response to sunitinib in renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2011, 29, 4627-4627.	0.8	13
135	A Recent Illustration of Some Essentials of Circadian Chronotherapy Study Design. <i>Journal of Clinical Oncology</i> , 2004, 22, 2971-2972.	0.8	12
136	Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. <i>Oncologist</i> , 2020, 25, 422-430.	1.9	12
137	Chronobiology Implications for cancer chemotherapy. <i>Acta Oncologica</i> , 1995, 34, 615-624.	0.8	11
138	Sunitinib dose-escalation after disease progression in metastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 12.e1-12.e6.	0.8	11
139	Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy. <i>Molecular Oncology</i> , 2018, 12, 1673-1688.	2.1	11
140	COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 425-435.e4.	0.9	11
141	Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 764-774.	0.4	11
142	Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. <i>Journal of Urology</i> , 2021, 205, 78-85.	0.2	11
143	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. <i>Canadian Urological Association Journal</i> , 2020, 15, 84-97.	0.3	11
144	It is time for chronotherapy!. <i>Pathologie Et Biologie</i> , 2003, 51, 197-200.	2.2	10

#	ARTICLE	IF	CITATIONS
145	Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 150-155.	0.9	10
146	Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2018, 13, 166-174.	0.3	10
147	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. <i>Canadian Urological Association Journal</i> , 2019, 13, 343-54.	0.3	10
148	Ibrutinib reprograms the glucocorticoid receptor in chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2019, 33, 1650-1662.	3.3	10
149	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis. <i>Journal of Geriatric Oncology</i> , 2021, 12, 820-826.	0.5	10
150	Menstrual cycle chronobiology: is it important in breast cancer screening and therapy?. <i>Lancet</i> , The, 1996, 347, 345-346.	6.3	9
151	Postoperative concurrent chronomodulated 5-fluorouracil/leucovorin infusion and pelvic radiotherapy for squamous cell carcinoma of the ovary arising from mature cystic teratoma. <i>International Journal of Gynecological Cancer</i> , 2001, 11, 418-421.	1.2	9
152	A unified prognostic model for first- and second-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from a large international study.. <i>Journal of Clinical Oncology</i> , 2010, 28, 4523-4523.	0.8	9
153	Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 396-396.	0.8	9
154	Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5024-5024.	0.8	9
155	A Four-Arm, Randomized, Multicenter Phase II Trial of Oxaliplatin Combined with Varying Schedules of 5-Fluorouracil as First-line Therapy in Previously Untreated Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2008, 7, 134-139.	1.0	8
156	Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence. <i>Clinical Drug Investigation</i> , 2018, 38, 1155-1165.	1.1	8
157	Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 521-530.	0.9	8
158	Diurnal rhythms (DR) in gene expression in human oral mucosa: Implications for gender differences in toxicity, response and survival and optimal timing of targeted therapy (Rx). <i>Journal of Clinical Oncology</i> , 2007, 25, 2507-2507.	0.8	8
159	Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU-leucovorin as first-line chemotherapy for metastatic colorectal cancer (MCC). <i>Journal of Clinical Oncology</i> , 2008, 26, 11032-11032.	0.8	8
160	Management of Advanced Kidney Cancer – Canadian Kidney Cancer Forum Consensus Update. <i>Canadian Urological Association Journal</i> , 2013, 7, 238.	0.3	7
161	Systemic therapy in metastatic renal cell carcinoma: Emerging challenges in therapeutic choice. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 152, 102971.	2.0	7
162	The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 398-398.	0.8	7

#	ARTICLE	IF	CITATIONS
163	Can individualized sunitinib dose and schedule changes optimize outcomes for kidney cancer patients?. Canadian Urological Association Journal, 2016, 10, 252.	0.3	6
164	Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. Canadian Urological Association Journal, 2017, 11, 310-320.	0.3	6
165	Integrated Molecular Analysis of Papillary Renal Cell Carcinoma and Precursor Lesions Unfolds Evolutionary Process from Kidney Progenitor-Like Cells. American Journal of Pathology, 2019, 189, 2046-2060.	1.9	6
166	Circadian robustness as an independent predictor of prolonged progression-free survival (PFS) and overall survival (OS) in 436 patients with metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2012, 30, 464-464.	0.8	6
167	Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1487-1495.	0.4	5
168	External validation of the International Metastatic Renal Cell Carcinoma (mRCC) Database Consortium prognostic model and comparison to four other models in the era of targeted therapy.. Journal of Clinical Oncology, 2011, 29, 4560-4560.	0.8	5
169	Effects of pazopanib (PAZ) and sunitinib (SUN) dose modification on safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZ.. Journal of Clinical Oncology, 2017, 35, 4574-4574.	0.8	5
170	Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers. European Urology Focus, 2022, 8, 1703-1710.	1.6	5
171	The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium.. Journal of Clinical Oncology, 2014, 32, 4576-4576.	0.8	4
172	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology, 2017, 35, 468-468.	0.8	4
173	Clinical chronotolerance to anticancer drugs: relevance for dose-intensity. In Vivo, 1995, 9, 557-64.	0.6	4
174	Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. Clinical Genitourinary Cancer, 2022, 20, 210-218.	0.9	4
175	Steroid-responsive interstitial lung disease in patients receiving 2-â€²-deoxy-5-fluorouridine-Infusion chemotherapy. A report of three cases. Cancer, 1995, 75, 2558-2564.	2.0	3
176	Nivolumab in the Treatment of Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1235-1242.	0.6	3
177	Diabetes and kidney cancer survival in patients undergoing nephrectomy: A Canadian multi-center, propensity score analysis. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 576.e11-576.e16.	0.8	3
178	Individualization of Dose and Schedule Based On Toxicity for Oral VEGF Drugs in Kidney Cancer. Kidney Cancer, 2019, 3, 213-225.	0.2	3
179	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e350-e359.	0.9	3
180	Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 559-566.	0.6	3

#	ARTICLE	IF	CITATIONS
181	Real-World Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). <i>Kidney Cancer</i> , 2021, 5, 21-29.	0.2	3
182	An individualized dose/schedule strategy for sunitinib in metastatic renal cell cancer (mRCC) on progression-free survival (PFS): Correlation with dynamic microbubble ultrasound (DCE-US) data.. <i>Journal of Clinical Oncology</i> , 2011, 29, e15149-e15149.	0.8	3
183	Efficacy of targeted drug therapy for metastatic renal cell carcinoma in the elderly patient population.. <i>Journal of Clinical Oncology</i> , 2011, 29, 318-318.	0.8	3
184	A multicentered population-based analysis of outcomes of patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials.. <i>Journal of Clinical Oncology</i> , 2012, 30, 353-353.	0.8	3
185	Contrasting the vascular response to sunitinib as measured by DCE-CT, DCE-MRI, and DCE-US.. <i>Journal of Clinical Oncology</i> , 2013, 31, 378-378.	0.8	3
186	Effect of the timing of sunitinib administration on the predictive value of biomarkers in renal cell cancer (mRCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 11096-11096.	0.8	3
187	Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 4555-4555.	0.8	3
188	Third-line therapy in metastatic renal cell carcinoma: Results from the International mRCC Database Consortium.. <i>Journal of Clinical Oncology</i> , 2015, 33, 430-430.	0.8	3
189	Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4514-4514.	0.8	3
190	Cabozantinib real-world effectiveness in the first through fourth-line settings for the treatment of metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 639-639.	0.8	3
191	Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS398-TPS398.	0.8	3
192	ABCC2 expression in papillary renal cell carcinoma provides better prognostic stratification than WHO/ISUP nucleolar grade. <i>Human Pathology</i> , 2022, 120, 57-70.	1.1	3
193	The future of precise cancer chronotherapeutics. <i>Lancet Oncology</i> , The, 2022, 23, e242.	5.1	3
194	Impact of Systemic Therapy in Metastatic Renal-Cell Carcinoma Patients With Synchronous and Metachronous Brain Metastases. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e224-e232.	0.9	2
195	Pharmacogenetic study in gastric cancer patients treated with adjuvant fluorouracil/leucovorin or epirubicin/cisplatin/fluorouracil before and after chemoradiation on CALGB 80101 (Alliance). <i>Pharmacogenetics and Genomics</i> , 2021, Publish Ahead of Print, 215-220.	0.7	2
196	Impact of bone and liver metastases (BM, LM) in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs): Results from the International mRCC Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 394-394.	0.8	2
197	Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 615-615.	0.8	2
198	Effect of an individualized dose/schedule strategy for sunitinib in metastatic renal cell cancer (mRCC) on progression-free survival (PFS): Correlation with dynamic microbubble ultrasound (DCE-US) data.. <i>Journal of Clinical Oncology</i> , 2011, 29, 356-356.	0.8	2

#	ARTICLE	IF	CITATIONS
199	Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.. Journal of Clinical Oncology, 2022, 40, 338-338.	0.8	2
200	Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma. Kidney Cancer, 2022, 6, 69-79.	0.2	2
201	Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98). Investigational New Drugs, 2005, 23, 51-56.	1.2	1
202	Preoperative Stereotactic Body Radiotherapy to a Skull Renal Cell Metastasis: An Alternative to Preoperative Embolization?. Journal of Palliative Medicine, 2011, 14, 157-160.	0.6	1
203	Isolated brain metastasis from a small renal mass. BMJ Case Reports, 2016, 2016, bcr2016216081.	0.2	1
204	Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience. Annals of Oncology, 2016, 27, vi285.	0.6	1
205	Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system. Canadian Urological Association Journal, 2020, 15, 132-137.	0.3	1
206	Phase III Study of 5-Fluorouracil, Leucovorin, Doxorubicin, Methotrexate, and Long-Term Oral Etoposide (FLAME) in Unresectable or Metastatic Gastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 1998, 21, 537-542.	0.6	1
207	Microbubble ultrasound compared to dynamic contrast MRI and CT for the assessment of vascular response to sunitinib in renal cell carcinoma.. Journal of Clinical Oncology, 2010, 28, e15039-e15039.	0.8	1
208	Chemotherapy-induced neutropenia association with survival in metastatic colorectal cancer (MCC): Schedule dependency.. Journal of Clinical Oncology, 2011, 29, 454-454.	0.8	1
209	Diurnal proteomics and biomarker discovery in indolent versus aggressive chronic lymphocytic leukemia patients.. Journal of Clinical Oncology, 2012, 30, 10622-10622.	0.8	1
210	Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway-targeted therapy and one prior mTOR inhibitor therapy.. Journal of Clinical Oncology, 2014, 32, 473-473.	0.8	1
211	Change in neutrophil to lymphocyte ratio as a prognostic and predictive marker in response to targeted therapy for metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 404-404.	0.8	1
212	The proportion and characterization of patients with metastatic renal cell carcinoma who are never treated or have delayed treatment with targeted therapy: Results from a large prospective cohort.. Journal of Clinical Oncology, 2015, 33, 424-424.	0.8	1
213	Outcomes of metastatic chromophobe renal cell carcinoma (chrRCC) in the targeted therapy era: Results from the International Metastatic Renal Cell Cancer Database Consortium.. Journal of Clinical Oncology, 2016, 34, 4570-4570.	0.8	1
214	Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.. Journal of Clinical Oncology, 2019, 37, 610-610.	0.8	1
215	Suppression of tumor progression and metastasis in renal cell carcinoma by miR-192, miR-194, and miR-215.. Journal of Clinical Oncology, 2013, 31, 385-385.	0.8	1
216	Metastatic non-clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Applying the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model to predict outcomes.. Journal of Clinical Oncology, 2013, 31, 396-396.	0.8	1

#	ARTICLE	IF	CITATIONS
217	Patient-reported sleep disruption as an independent prognostic factor for overall survival in metastatic colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 410-410.	0.8	1
218	Third-line therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).. Journal of Clinical Oncology, 2015, 33, e15578-e15578.	0.8	1
219	Objective sleep duration (SD) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCC).. Journal of Clinical Oncology, 2016, 34, 511-511.	0.8	1
220	Outcomes of Radiation Therapy Plus Immunotherapy in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Advances in Radiation Oncology, 2022, 7, 100899.	0.6	1
221	Clinical cancer chronotherapy trials: a review. The Journal of Infusional Chemotherapy, 1995, 5, 31-7.	0.1	1
222	Adjuvant therapy with fluorouracil and levamisole and liver ultrasound mimicking liver metastases.. Journal of Clinical Oncology, 1994, 12, 1335-1336.	0.8	0
223	Reply to letter by M. Smolensky and L. T. Campos. Cancer Chemotherapy and Pharmacology, 1994, 34, 271-272.	1.1	0
224	P468 Sleep fragmentation due to sleep disordered breathing in cluster headache patients. Sleep Medicine, 2006, 7, S119-S120.	0.8	0
225	Towards Comprehensive Clinical Trial Reporting: The Value of Unpublished Data to Inform Therapeutic Decision-Making in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2019, 17, e1181-e1184.	0.9	0
226	Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC). Journal of Cancer Education, 2019, 34, 14-18.	0.6	0
227	Reply By Authors. Journal of Urology, 2021, 205, 84-85.	0.2	0
228	Can incomplete metastasectomy impact renal cell carcinoma outcomes? A propensity score matching analysis from a prospective multicenter collaboration. Soci�t� Internationale D'urologie Journal, 2021, 2, 82-95.	0.2	0
229	Altered circadian rhythm in rest and activity (CircAct): Independent prognostic value for survival in patients (pts) with metastatic colorectal cancer (MCC). Journal of Clinical Oncology, 2007, 25, 14573-14573.	0.8	0
230	Relevance of circadian coordination for the outcome of patients with advanced gastro-intestinal (GI) cancer. Journal of Clinical Oncology, 2008, 26, 15043-15043.	0.8	0
231	Chemotherapy-induced neutropenia (neutro) association with survival in metastatic colorectal cancer (MCC): Schedule dependency.. Journal of Clinical Oncology, 2011, 29, e13024-e13024.	0.8	0
232	Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies. , 2012, , 265-283.		0
233	Conditional survival (CS) for patients with metastatic renal cell carcinoma (mRCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy (TT): Results from the International mRCC Database Consortium.. Journal of Clinical Oncology, 2012, 30, 358-358.	0.8	0
234	Improving outcomes through the development of quality indicators in renal cell cancer.. Journal of Clinical Oncology, 2012, 30, 422-422.	0.8	0

#	ARTICLE	IF	CITATIONS
235	Tumor suppressor effects for miR-215 identified through use of miRNA profiling in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2012, 30, 392-392.	0.8	0
236	Pleotrophic action of renal cell carcinoma: Dysregulated microRNAs on hypoxia-related signaling pathways.. Journal of Clinical Oncology, 2012, 30, 428-428.	0.8	0
237	Use of miRNA profiling in metastatic renal cell carcinoma to reveal a tumor suppressor effect for mir-215.. Journal of Clinical Oncology, 2012, 30, 4633-4633.	0.8	0
238	Relative quantification of protein expression in metastatic renal cell carcinoma using iTRAQ LC-MS/MS analysis reveals galectin-1 as a potential prognostic marker and therapeutic target.. Journal of Clinical Oncology, 2013, 31, 412-412.	0.8	0
239	Diurnal proteomics and biomarker discovery in indolent versus aggressive chronic lymphocytic leukemia (CLL) patients: A proof of principle pilot study.. Journal of Clinical Oncology, 2014, 32, e22220-e22220.	0.8	0
240	Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies. , 2015, , 365-384.		0
241	Subjective sleep problems and objective circadian disruption: Impact on outcomes in patients with metastatic colorectal cancer (MCC).. Journal of Clinical Oncology, 2015, 33, e14584-e14584.	0.8	0
242	Characterizing the outcomes of metastatic papillary renal cell carcinoma (papRCC).. Journal of Clinical Oncology, 2016, 34, 4554-4554.	0.8	0
243	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).. Journal of Clinical Oncology, 2016, 34, 4510-4510.	0.8	0
244	Eligibility criteria and endpoints in metastatic renal cell carcinoma trials.. Journal of Clinical Oncology, 2017, 35, 465-465.	0.8	0
245	Sunitinib dose escalation after disease progression in metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2017, 35, 458-458.	0.8	0
246	Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).. Journal of Clinical Oncology, 2017, 35, e16078-e16078.	0.8	0
247	Nivolumab in the treatment of metastatic renal cell carcinoma: A cost-utility analysis.. Journal of Clinical Oncology, 2017, 35, e18331-e18331.	0.8	0
248	Abstract 5599: Soluble PD-L1 as a surrogate biomarker of metastatic progression and resistance to antiangiogenic therapy. , 2017, , .		0
249	Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.. Journal of Clinical Oncology, 2018, 36, 667-667.	0.8	0
250	Evaluation of RNA-sequencing (RNA-seq) signatures with pembrolizumab (pembro) in patients (pts) with renal cell carcinoma (RCC) from KEYNOTE-427 cohort A.. Journal of Clinical Oncology, 2020, 38, 729-729.	0.8	0
251	The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance. Journal of Clinical Medicine, 2022, 11, 369.	1.0	0
252	Formal clinical evaluation of the CADD-Micro system for circadian delivery of FUDR in patients with metastatic renal cell cancer. The Journal of Infusional Chemotherapy, 1995, 5, 82-8.	0.1	0

#	ARTICLE	IF	CITATIONS
253	Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).. Journal of Clinical Oncology, 2022, 40, 304-304.	0.8	0